Matthew Boudreau, a chemistry PhD candidate in the CCIL Deputy Director Paul Hergenrother’s lab, has been awarded the prestigious F99/K00 grant from the National Cancer Institute (NCI). Boudreau’s research has centered around a novel therapeutic, ERSO, that successfully eradicates
Paul Hergenrother helps discover cancer compound now in licensing deal. Researchers affiliated with the Cancer Center at Illinois discovered a novel small molecule compound that is now the subject of a new global licensing agreement between the pharmaceutical company Bayer
Riley Svec was awarded a position on the NIH Chemistry-Biology Interface Training Grant. He was an Advanced Graduate Student speaker at the 15th Annual Symposium on Friday, October 4, 2019.
Gram-negative bacteria have emerged that are resistant to most antibiotics, a troubling trend since a new class of antibiotics for Gram-negative pathogens has not been introduced in the clinic in 50 years. Central to the issue with discovering novel antibiotics
We congratulate graduate student Martin Garcia Chavez and undergraduate Amanda Cowfer for being awarded NSF Research Fellowships!
Dr. Riley was awarded an F32 postdoctoral fellowship from the NIH!
Clinical trials on companion animals diagnosed with cancer have brought new hope to their owners—and new data for a cutting-edge cancer drug being developed by scientists at Illinois.
By Mary Timmins
On the day we meet Pretzel, the weather is
A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib